ArticleGynecologic oncology reports2026
Durable complete remission of pulmonary metastases with bevacizumab plus olaparib maintenance therapy in homologous recombination-deficient gynecologic large-cell neuroendocrine carcinoma: A case report.
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gynecologic neuroendocrine carcinoma (NEC) is a rare and aggressive malignancy with limited treatment options and poor prognosis. Homologous recombination deficiency (HRD) is an established predictive biomarker for poly(ADP-ribose) polymerase (PARP) inhibitor response in ovarian cancer, but its clinical relevance in NEC remains unclear. Case presentation A 71-year-old woman presented with a large pelvic mass and multiple pulmonary metastases. Primary debulking surgery was performed, and histopathology revealed large-cell NEC (LCNEC) of presumed gynecologic origin. Postoperatively, the patient received paclitaxel-carboplatin plus bevacizumab. HRD testing demonstrated a high genomic instability score without BRCA1/2 mutations. After six cycles of chemotherapy, the pulmonary lesions showed a partial response. Maintenance therapy with bevacizumab plus olaparib was initiated, and the patient achieved complete radiologic remission, remaining disease-free for 1 year. Conclusion HRD-positive gynecologic NEC may respond to PARP inhibitor-based therapy even in the absence of BRCA mutations. HRD assessment may help identify patients with NEC who could benefit from targeted treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.